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Screening Strategies for Hepatitis C Virus
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Since May 2016, the World Health Organization (WHO) has advocated for the elimination of hepatitis C virus (HCV) as a public health threat 
by 2030, defined as an 80% reduction in HCV inci-
dence and 65% reduction in HCV-related mortality 
compared with 2015. Targets for achieving these goals 
include reaching service-coverage targets of diagnos-
ing 90% and treating 80% of chronic HCV infec-
tions.(1) This elimination goal was driven by recent 
advances in the development of highly effective HCV 
direct-acting antivirals (DAAs).(2) However, it is esti-
mated that less than 20% of all chronically infected 
individuals were aware of their infection status in 
2015 (Fig. 1).(1) This highlights that case-finding 
will be a major challenge for scaling up treatment to 
reach the WHO elimination goals, especially in low- 
and middle-income country (LMIC) settings where 
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limitations in resource and health care infrastructure 
create additional barriers to accessing treatment.
In most countries, higher prevalence of infection 
and HCV-related comorbidities are usually concen-
trated in key subpopulations that have risk factors 
associated with HCV exposure, such as people who 
inject drugs (PWID), men who have sex with men, 
prisoners, individuals with high-risk health care or 
community exposures, and patients with liver condi-
tions. Recent modeling studies in both LMIC and 
high-income country (HIC) settings have suggested 
that prioritizing screening and treatment to such pop-
ulations can facilitate reaching the WHO HCV elim-
ination goals; therefore, identifying these groups is 
critical for designing targeted screening programs.(3,4)
In this issue of Hepatology Communications, 
Chemaitelly et al.(5) explore the issue of whom should 
be tested for HCV, concentrating on the Middle 
East and North Africa (MENA) region (including 
Afghanistan, Iran, and Pakistan), which has a dis-
proportionate burden of infection and disease. They 
estimate the numbers needing to be tested to iden-
tify one chronically infected individual for six broad 
epidemiological subpopulations (categorized by the 
perceived risk of HCV infection exposure), referred to 
as the “yield” of testing. These subpopulations were, 
namely, PWID, those with liver conditions, those with 
high-risk health care exposures, those at intermediate 
risk, special clinical populations, and general low-risk 
populations. The study’s strength is that it draws upon 
a comprehensive, systematically generated database 
of HCV seroprevalence estimates derived from over 
2,500 studies encompassing 49 million persons across 
24 countries of the MENA region, most of which 
are LMICs. The authors distinguish between “gen-
eralized” versus “concentrated” HCV epidemics, in 
which generalized epidemics were defined as having 
a HCV seroprevalence of 3% or greater among the 
general population (Egypt and Pakistan) and concen-
trated epidemics as less than 3% HCV seroprevalence 
(remaining countries in region). Concentrated epi-
demics were usually characterized by high HCV prev-
alence in one or more subpopulations (e.g., PWID or 
those with high-risk health care exposures), but with 
little dissemination in the general population. By 
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ranking the anticipated yields of chronic HCV cases 
from screening different subpopulations, the authors 
identify distinct pathways for how testing programs 
should expand, depending on the epidemic type.
For both generalized and concentrated epidemics, 
prioritization of screening in key populations should 
come first and continue in order of diminishing 
yield. In the case of generalized epidemics, identify-
ing chronically infected individuals through screening 
higher-risk groups will be effective at program initi-
ation (e.g., requiring 2.5 tests per chronic infection 
among PWID), whereas reasonable yields should still 
be possible when testing is expanded (e.g., 15 tests per 
chronic infection). In contrast, concentrated epidem-
ics demonstrated starker diminishing returns, with 
rapidly decreasing yield from 2.8 tests per chronic 
infection diagnosed among PWID to over 220 in 
the general population. This suggests that widespread 
testing may not be cost-effective in lower prevalence 
settings.
However, despite the conclusions of Chemaitelly 
et al. that a general population screening approach in 
concentrated epidemics may not be efficient, it may 
still be necessary to reach the WHO HCV elimina-
tion goals in many settings, as the higher HCV prev-
alence groups may not contain sufficient numbers 
of infections. This highlights the need for further 
studies to assess the yield, reach, cost-effectiveness, 
and budgetary implications of different screening 
strategies, including those that use more detailed 
risk-based algorithms. For instance, in Pakistan we 
showed a clear trend for increasing HCV prevalence 
with accumulation of multiple medical and commu-
nity risk factors.(6) Linking such analyses with eco-
nomic modeling is particularly crucial in LMICs, 
where resource prioritization is necessary to ensure 
the greatest impact with limited resources. As prices 
of DAA treatments fall and generic drugs become 
more widely available,(2) an increasing proportion of 
costs will be attributed to testing. Even in gener-
alized epidemic settings where general population 
case-finding can effectively identify chronic HCV 
infections, as prevalence declines, so does the yield, 
which will lead to a substantial increase in the strain 
on resources.
Treating high-risk subpopulations that are consid-
ered difficult to engage with, such as PWID, is still 
effective,(7) and the work by Chemaitelly et al. empha-
sizes that treatment programs should be targeted to 
these marginalized individuals to maximize the screen-
ing yield. Although there are many estimates of HCV 
prevalence among high-risk subpopulations, especially 
PWID, what is often not well-known is the size of 
these populations and how important they are to the 
Fig. 1. Cascade of care for HCV infection by WHO region in 2015. Figure reproduced, with permission, from WHO Global 
Hepatitis Report 2017.(1)
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overall epidemic. For instance, whereas PWID play a 
prominent role in many HICs with concentrated epi-
demics, their role in most LMICs and more general-
ized epidemics is less understood. Further studies are 
needed to give clearer estimates on the numbers of 
infections present and their distributions, which will 
elucidate the extent of testing required in each group. 
More broadly, a greater amount of high-quality data 
will improve the estimates of risk, yield, and hierarchy 
of testing strategies, particularly for specific subpopu-
lations but also in the general population.
Better data on how HCV prevalence varies within 
countries are also needed, as this can exhibit a great 
deal of heterogeneity, with some experiencing gen-
eralized HCV epidemic characteristics, while others 
hosting concentrated epidemics. An example of this 
is Pakistan, where Punjab and Sindh provinces have 
generalized epidemics, with provincial HCV sero-
prevalence estimates of 6.7% and 5.0%, respectively, 
whereas Balochistan and the northwestern province of 
Khyber Pakhtunkhwa have far lower HCV seropreva-
lences (1.5% and 1.1%, respectively) and concentrated 
epidemics.(8) These variations highlight the need for 
efficient screening strategies that are tailored to the 
subregions of each country.
Stakeholders, including governmental health 
departments, nongovernmental organizations, and 
other health care providers, need to navigate the con-
cept of “micro-elimination.”(9) This strategy seeks 
to break down country-level elimination goals into 
smaller and more manageable targets that are geared 
toward achieving elimination in defined subpopula-
tions. Lessons learned from micro-elimination strat-
egies in diverse contexts can then be applied more 
widely to alternative contexts within the same country 
or to other countries. For instance, from 2015-2016, 
the Egyptian Liver Research Institute and Hospital 
launched a community-based micro-elimination proj-
ect to educate, test, and treat HCV in a village in 
northern Egypt. The findings were used to comple-
ment not only the national government HCV elim-
ination program, but also provide insights that could 
help inform planning in other high HCV-prevalent 
countries with large rural populations, such as 
Pakistan, Mongolia, or Indonesia.(10) Egypt’s national 
HCV screening and treatment program is an exemplar 
for other countries to follow, not only in the MENA 
region, but also worldwide. Notably, since launching 
the “100 Million Health” initiative in October 2018, 
approximately 23 million people in Egypt have been 
screened in a period of 90 days in 2018 (Government 
of Egypt State Information Service, Press Release on 
December 29, 2018), accounting for almost one-quar-
ter of the country’s population. The HCV screening 
program in Egypt demonstrates the scale that can be 
achieved in LMICs if there is the political will to act.
As HCV treatment is now highly effective, the main 
priority and challenge is to efficiently identify infected 
individuals to treat. The study by Chemaitelly et al. 
presents the best available data for HCV screening 
in the MENA region, suggesting potential strategies 
for efficiently scaling up active case-finding of HCV. 
The findings highlight the need to prioritize high-risk 
populations such as those with liver conditions and 
high-risk health care exposures, as well as marginal-
ized populations such as PWID and prisoners. Further 
research expanding the ideas in this study, especially 
on using epidemiological data and cost-effectiveness 
 analyses to tailor screening strategies to the context 
and resources available in different countries, could 
pave the way for establishing effective strategies for 
HCV elimination that can serve as examples in other 
contexts.
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